Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics receives approval to advance clinical studies

Results from the phase Ib study are expected during this September quarter.
cat lying on a dog
The cannabis-derived pain control drug candidate CPAT-01 is targeting cats and dogs

CannPal Animal Therapeutics Ltd (ASX:CP1) has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain control in dogs.

Phase Ib is a continuation of research into CPAT-01, an innovative cannabis-derived pain control being developed for both cats and dogs.

Set to commence this month, phase Ib of the pharmacokinetic and safety study has recruited 48 dogs for the study.

READ: CannPal Animal Therapeutics positioned in a growing animal health market

CannPal's managing director Layton Mills said: “We’re very pleased to have received ethics approval for our phase Ib study for CPAT-01.

“The speed with which CannPal has moved to the next stage of our research is indicative of our commitment to progressing our clinical development plans on time.

“We look forward to further updating the market on the results of this study, which are expected in Q3 2018.”

Study also assessing tolerability

The study design will be assessing additional pharmacokinetic and safety parameters, including tolerability at five times the estimated dose, and early dose ranging confirmation.

The company is also evaluating the cannabinoid impact on identified gene expression targets to identify underlying mechanisms of action.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

cannabis tablet
March 01 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
cannabis plant
May 06 2019
The cannabis company invests in income-producing property and provides financing solutions and capital investment to service the blossoming cannabis industry
cannabis plant
June 17 2019
The company recently underwent a brand identity redesign and unveiled a new wknd! product line consisting of pre-rolls, vape pens and cannagars which it will launch in July in Washington State

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use